ArticleDiscover nano2026
Tamoxifen loaded lipid nanoparticles as a novel therapeutic approach enhancing apoptotic cell death in triple negative breast cancer cells.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tamoxifen (TMX), a selective estrogen receptor modulator, is widely used to treat hormone-dependent breast cancer (BC). Nevertheless, low bioavailability, and emerging deleterious effects considerably restrict TMX clinical application. This study aimed to develop and comprehensively characterize TMX-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), to comparatively assess their physicochemical performance and to evaluate their therapeutic potential against triple-negative BC (TNBC). After production, those lipid nanoparticles (LNPs) were characterized in terms of particle size, polydispersity index, zeta potential, morphological investigation through transmission electron microscopy analysis, identifications of interactions via FT-IR and differential scanning calorimetry, entrapment efficiency, drug loading, drug release study, long-term stability for 7 months, cell viability and flow cytometry analysis to evaluate antitumor efficacy of drug carriers. TMX loaded LNPs (15 mg) were produced with small size (< 200 nm), homogeneous dispersion (< 0.3) and high entrapment efficiency (> 90%). FT-IR spectra and differential scanning calorimetry profiles confirmed TMX conjugation into LNPs. TMX showed higher release from NLCs, whereas SLNs showed retarded release. Particle concentration was reduced 10-30 times after TMX loading. Moreover, TMX-loaded LNPs effectively inhibited cell viability on TNBC (MDA-MB-231), mainly based on apoptosis. These findings suggest that TMX-loaded LNPs represent a promising preclinical strategy for enhancing TMX efficacy against TNBC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.